ALX Oncology Announces ASPEN-03 And ASPEN-04 Phase 2 Trials Evaluating Evorpacept With A Checkpoint Inhibitor For The Treatment Of Head And Neck Cancers Did Not Meet Primary Endpoints

BenzingaApr 25 09:03 ET

Express News | ALX Oncology Reports Aspen-03 and Aspen-04 Phase 2 Trials Evaluating Evorpacept With a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

ReutersApr 25 09:00 ET

Condo Resale Prices Down in March Whilst Volumes Log Double-digit Growth

Singapore Business ReviewApr 24 23:23 ET

Singapore's Private Residential Price Index Up 0.8% in Q1

MT NewswiresApr 24 22:10 ET

Property Market Resilience Hinges on Tariff-driven Job and Cost Pressures

Singapore Business ReviewApr 24 18:00 ET

Shophouse Sales Fall 43% QoQ to $100m in Q1: Report

Singapore Business ReviewApr 24 17:00 ET